JP2021520368A5 - - Google Patents
Info
- Publication number
- JP2021520368A5 JP2021520368A5 JP2020554198A JP2020554198A JP2021520368A5 JP 2021520368 A5 JP2021520368 A5 JP 2021520368A5 JP 2020554198 A JP2020554198 A JP 2020554198A JP 2020554198 A JP2020554198 A JP 2020554198A JP 2021520368 A5 JP2021520368 A5 JP 2021520368A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- tumor
- poliovirus
- immune checkpoint
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651470P | 2018-04-02 | 2018-04-02 | |
| US62/651,470 | 2018-04-02 | ||
| US201962823277P | 2019-03-25 | 2019-03-25 | |
| US62/823,277 | 2019-03-25 | ||
| PCT/US2019/025402 WO2019195302A1 (en) | 2018-04-02 | 2019-04-02 | Neoadjuvant cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520368A JP2021520368A (ja) | 2021-08-19 |
| JP2021520368A5 true JP2021520368A5 (https=) | 2022-04-12 |
| JP7550449B2 JP7550449B2 (ja) | 2024-09-13 |
Family
ID=68101391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554198A Active JP7550449B2 (ja) | 2018-04-02 | 2019-04-02 | ネオアジュバントがん治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20210106633A1 (https=) |
| EP (1) | EP3773650A4 (https=) |
| JP (1) | JP7550449B2 (https=) |
| KR (1) | KR20200139738A (https=) |
| CN (2) | CN112118853A (https=) |
| AU (1) | AU2019247039B2 (https=) |
| CA (1) | CA3095591A1 (https=) |
| WO (1) | WO2019195302A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018067446A1 (en) | 2016-10-06 | 2018-04-12 | Duke University | Detection of cd-155, the poliovirus receptor |
| EP3525822A4 (en) | 2016-10-17 | 2020-05-06 | Duke University | PRODUCTION OF IMMUNOTOXIN D2C7- (SCDSFV) -PE38KDEL |
| US20220387529A1 (en) * | 2019-11-04 | 2022-12-08 | Duke University | Treatment for primary and metastatic cancer |
| WO2023141236A2 (en) * | 2022-01-19 | 2023-07-27 | Istari Oncology, Inc. | Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus |
| EP4466000A2 (en) * | 2022-01-19 | 2024-11-27 | Istari Oncology, Inc. | Oncolytic virus regimens for the treatment of cancer |
| CN114931637B (zh) * | 2022-06-27 | 2025-02-18 | 中山大学中山眼科中心 | Pdl1抗体在角膜新生血管疾病中的应用 |
| WO2025019822A1 (en) * | 2023-07-19 | 2025-01-23 | Istari Oncology, Inc. | Methods of treatment with a chimeric poliovirus in patients with glioblastoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104936608A (zh) * | 2012-11-21 | 2015-09-23 | 杜克大学 | 用于人肿瘤的溶瘤脊髓灰质炎病毒 |
| WO2017066557A1 (en) * | 2015-10-15 | 2017-04-20 | Duke University | Combination treatment |
| ES2994611T3 (en) * | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| CN108367070B (zh) * | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| WO2017156349A1 (en) * | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| CN108883186B (zh) * | 2016-03-21 | 2022-02-01 | 杜克大学 | 序贯抗癌治疗 |
| US20190202886A1 (en) * | 2016-05-11 | 2019-07-04 | Ohio State Innovation Foundation | ONCOLYTIC VIRUSES COMPRISING esRAGE AND METHODS OF TREATING CANCER |
| CN109789177A (zh) * | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| US20220387529A1 (en) * | 2019-11-04 | 2022-12-08 | Duke University | Treatment for primary and metastatic cancer |
-
2019
- 2019-04-02 JP JP2020554198A patent/JP7550449B2/ja active Active
- 2019-04-02 CN CN201980032645.4A patent/CN112118853A/zh active Pending
- 2019-04-02 EP EP19780949.4A patent/EP3773650A4/en not_active Withdrawn
- 2019-04-02 KR KR1020207031272A patent/KR20200139738A/ko not_active Ceased
- 2019-04-02 US US17/044,645 patent/US20210106633A1/en not_active Abandoned
- 2019-04-02 AU AU2019247039A patent/AU2019247039B2/en active Active
- 2019-04-02 CA CA3095591A patent/CA3095591A1/en active Pending
- 2019-04-02 CN CN202311455142.2A patent/CN117414421A/zh active Pending
- 2019-04-02 WO PCT/US2019/025402 patent/WO2019195302A1/en not_active Ceased
-
2025
- 2025-03-03 US US19/068,967 patent/US20250241969A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520368A5 (https=) | ||
| Ventola | Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations | |
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| JP4576005B2 (ja) | 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ | |
| EP3581182B1 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2020500181A5 (https=) | ||
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| BR122023025321A2 (pt) | Uso de anticorpos anti-b7-h1 e anti-ctla-4 | |
| WO2013189516A1 (en) | Method for treating a gd2 positive cancer | |
| CN109475576A (zh) | 用于治疗her2阳性转移性乳腺癌的组合物和方法 | |
| JP2020183447A5 (https=) | ||
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| Gervaso et al. | Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe? | |
| JP2023505222A5 (https=) | ||
| WO2017120997A1 (zh) | 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR的转基因淋巴细胞及其用途 | |
| Serre et al. | Brachytherapy: perspectives for combined treatments with immunotherapy | |
| CN111867598A (zh) | 肿瘤免疫赋活剂 | |
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| BR112020025203A2 (pt) | Materiais e métodos para tratar distúrbios relacionados o estresse e câncer | |
| US20240001142A1 (en) | Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy | |
| US20220265716A1 (en) | Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis | |
| Arabpour et al. | Cancer immunotherapy | |
| WO2009147695A1 (ja) | 抗がん剤 | |
| EP4681707A1 (en) | Method for treating diseases by using reparixin alone or in combination with anti-pd-1 antibody |